Daniel R. Chevallard - 16 Mar 2023 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role: CFO and COO
Signature: /s/ Daniel Chevallard
Issuer symbol: VIRX
Transactions as of: 16 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 17 Mar 2023, 16:57:12 UTC
Previous filing: 28 Feb 2023
Next filing: 26 May 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIRX	Stock Option (Right to Buy)	Award	$0	+200,000		$0.000000	200,000	16 Mar 2023	Common Stock	200,000	$1.65	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2023.

Content

1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2023.